<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title38.html">
                                    Title 38
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/38CFR4.html">Part 4
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  4.87  Schedule of ratings--ear.
                            </h3>
                            <p class="depth0">Diseases of the Ear------------------------------------------------------------------------</p><p class="depth0">Rating------------------------------------------------------------------------6200 Chronic suppurative otitis media, mastoiditis, or</p><p class="depth0">cholesteatoma (or any combination):</p><p class="depth0">During suppuration, or with aural polyps......................      10</p><p class="depth0">Note: Evaluate hearing impairment, and complications such as</p><p class="depth0">labyrinthitis, tinnitus, facial nerve paralysis, or bone loss</p><p class="depth0">of skull, separately.6201 Chronic nonsuppurative otitis media with effusion (serous</p><p class="depth0">otitis media):</p><p class="depth0">Rate hearing impairment6202 Otosclerosis:</p><p class="depth0">Rate hearing impairment6204 Peripheral vestibular disorders:</p><p class="depth0">Dizziness and occasional staggering...........................      30</p><p class="depth0">Occasional dizziness..........................................      10</p><p class="depth0">Note: Objective findings supporting the diagnosis of</p><p class="depth0">vestibular disequilibrium are required before a compensable</p><p class="depth0">evaluation can be assigned under this code. Hearing</p><p class="depth0">impairment or suppuration shall be separately rated and</p><p class="depth0">combined.6205 Meniere's syndrome (endolymphatic hydrops):</p><p class="depth0">Hearing impairment with attacks of vertigo and cerebellar gait     100</p><p class="depth0">occurring more than once weekly, with or without tinnitus....</p><p class="depth0">Hearing impairment with attacks of vertigo and cerebellar gait      60</p><p class="depth0">occurring from one to four times a month, with or without</p><p class="depth0">tinnitus.....................................................</p><p class="depth0">Hearing impairment with vertigo less than once a month, with        30</p><p class="depth0">or without tinnitus..........................................</p><p class="depth0">Note: Evaluate Meniere's syndrome either under these criteria</p><p class="depth0">or by separately evaluating vertigo (as a peripheral</p><p class="depth0">vestibular disorder), hearing impairment, and tinnitus,</p><p class="depth0">whichever method results in a higher overall evaluation. But</p><p class="depth0">do not combine an evaluation for hearing impairment,</p><p class="depth0">tinnitus, or vertigo with an evaluation under diagnostic code</p><p class="depth0">6205.6207 Loss of auricle:</p><p class="depth0">Complete loss of both.........................................      50</p><p class="depth0">Complete loss of one..........................................      30</p><p class="depth0">Deformity of one, with loss of one-third or more of the             10</p><p class="depth0">substance....................................................6208 Malignant neoplasm of the ear (other than skin only).......     100</p><p class="depth0">Note: A rating of 100 percent shall continue beyond the</p><p class="depth0">cessation of any surgical, radiation treatment,</p><p class="depth0">antineoplastic chemotherapy or other therapeutic procedure.</p><p class="depth0">Six months after discontinuance of such treatment, the</p><p class="depth0">appropriate disability rating shall be determined by</p><p class="depth0">mandatory VA examination. Any change in evaluation based on</p><p class="depth0">that or any subsequent examination shall be subject to the</p><p class="depth0">provisions of Sec.   3.105(e) of this chapter. If there has</p><p class="depth0">been no local recurrence or metastasis, rate on residuals.6209 Benign neoplasms of the ear (other than skin only):</p><p class="depth0">Rate on impairment of function.6210 Chronic otitis externa:</p><p class="depth0">Swelling, dry and scaly or serous discharge, and itching            10</p><p class="depth0">requiring frequent and prolonged treatment...................6211 Tympanic membrane, perforation of..........................       06260 Tinnitus, recurrent........................................      10</p><p class="depth0">Note (1): A separate evaluation for tinnitus may be combined</p><p class="depth0">with an evaluation under diagnostic codes 6100, 6200, 6204,</p><p class="depth0">or other diagnostic code, except when tinnitus supports an</p><p class="depth0">evaluation under one of those diagnostic codes.</p><p class="depth0">Note (2): Assign only a single evaluation for recurrent</p><p class="depth0">tinnitus, whether the sound is perceived in one ear, both</p><p class="depth0">ears, or in the head.</p><p class="depth0">Note (3): Do not evaluate objective tinnitus (in which the</p><p class="depth0">sound is audible to other people and has a definable cause</p><p class="depth0">that may or may not be pathologic) under this diagnostic</p><p class="depth0">code, but evaluate it as part of any underlying condition</p><p class="depth0">causing it.------------------------------------------------------------------------

(Authority: 38 U.S.C. 1155)
[64 FR 25210, May 11, 1999, as amended at 68 FR 25823, May 14, 2003]


Sec.  4.87a  Schedule of ratings--other sense organs.
------------------------------------------------------------------------</p><p class="depth0">Rating------------------------------------------------------------------------6275 Sense of smell, complete loss..............................      106276 Sense of taste, complete loss..............................      10</p><p class="depth0">Note: Evaluation will be assigned under diagnostic codes 6275</p><p class="depth0">or 6276 only if there is an anatomical or pathological basis</p><p class="depth0">for the condition.------------------------------------------------------------------------

(Authority: 38 U.S.C. 1155)
[64 FR 25210, May 11, 1999]</p><p class="depth0">Infectious Diseases, Immune Disorders and Nutritional Deficiencies


Sec.  4.88  [Reserved]


Sec.  4.88a  Chronic fatigue syndrome.</p><p class="depth0"><em>(a)</em> For VA purposes, the diagnosis of chronic fatigue syndrome requires:</p><p class="depth0"><em>(1)</em> new onset of debilitating fatigue severe enough to reduce daily activity to less than 50 percent of the usual level for at least six months; and</p><p class="depth0"><em>(2)</em> the exclusion, by history, physical examination, and laboratory tests, of all other clinical conditions that may produce similar symptoms; and</p><p class="depth0"><em>(3)</em> six or more of the following:</p><p class="depth0"><em>(i)</em> acute onset of the condition,</p><p class="depth0"><em>(ii)</em> low grade fever,</p><p class="depth0"><em>(iii)</em> nonexudative pharyngitis,</p><p class="depth0"><em>(iv)</em> palpable or tender cervical or axillary lymph nodes,</p><p class="depth0"><em>(v)</em> generalized muscle aches or weakness,</p><p class="depth0"><em>(vi)</em> fatigue lasting 24 hours or longer after exercise,</p><p class="depth0"><em>(vii)</em> headaches (of a type, severity, or pattern that is different from headaches in the pre-morbid state),</p><p class="depth0"><em>(viii)</em> migratory joint pains,</p><p class="depth0"><em>(ix)</em> neuropsychologic symptoms,</p><p class="depth0"><em>(x)</em> sleep disturbance.</p><p class="depth0"><em>(b)</em> [Reserved]
[59 FR 60902, Nov. 29, 1994]


Sec.  4.88b  Schedule of ratings--infectious diseases, immune disorders and nutritional deficiencies.
------------------------------------------------------------------------</p><p class="depth0">Rating------------------------------------------------------------------------6300 Cholera, Asiatic:</p><p class="depth0">As active disease, and for 3 months convalescence......         100</p><p class="depth0">Thereafter rate residuals such as renal necrosis under the</p><p class="depth0">appropriate system6301 Visceral Leishmaniasis:</p><p class="depth0">During treatment for active disease....................          100</p><p class="depth0">Note: A 100 percent evaluation shall continue beyond the cessation</p><p class="depth0">of treatment for active disease. Six months after discontinuance of</p><p class="depth0">such treatment, the appropriate disability rating shall be</p><p class="depth0">determined by mandatory VA examination. Any change in evaluation</p><p class="depth0">based upon that or any subsequent examination shall be subject to</p><p class="depth0">the provisions of Sec.   3.105(e) of this chapter. Rate residuals</p><p class="depth0">such as liver damage or lymphadenopathy under the appropriate</p><p class="depth0">system.</p><p class="depth0">6302 Leprosy (Hansen's Disease):</p><p class="depth0">As active disease......................................          100</p><p class="depth0">Note: A 100 percent evaluation shall continue beyond the date that</p><p class="depth0">an examining physician has determined that this has become</p><p class="depth0">inactive. Six months after the date of inactivity, the appropriate</p><p class="depth0">disability rating shall be determined by mandatory VA examination.</p><p class="depth0">Any change in evaluation based upon that or any subsequent</p><p class="depth0">examination shall be subject to the provisions of Sec.   3.105(e)</p><p class="depth0">of this chapter. Rate residuals such as skin lesions or peripheral</p><p class="depth0">neuropathy under the appropriate system.</p><p class="depth0">6304 Malaria:</p><p class="depth0">As active disease......................................          100</p><p class="depth0">Note: The diagnosis of malaria depends on the identification of the</p><p class="depth0">malarial parasites in blood smears. If the veteran served in an</p><p class="depth0">endemic area and presents signs and symptoms compatible with</p><p class="depth0">malaria, the diagnosis may be based on clinical grounds alone.</p><p class="depth0">Relapses must be confirmed by the presence of malarial parasites in</p><p class="depth0">blood smears.</p><p class="depth0">Thereafter rate residuals such as liver or spleen damage under the</p><p class="depth0">appropriate system</p><p class="depth0">6305 Lymphatic Filariasis:</p><p class="depth0">As active disease......................................         100</p><p class="depth0">Thereafter rate residuals such as epididymitis or lymphangitis under</p><p class="depth0">the appropriate system6306 Bartonellosis:</p><p class="depth0">As active disease, and for 3 months convalescence......         100</p><p class="depth0">Thereafter rate residuals such as skin lesions under the appropriate</p><p class="depth0">system6307 Plague:</p><p class="depth0">As active disease......................................         100</p><p class="depth0">Thereafter rate residuals such as lymphadenopathy under the</p><p class="depth0">appropriate system6308 Relapsing Fever:</p><p class="depth0">As active disease......................................         100</p><p class="depth0">Thereafter rate residuals such as liver or spleen damage or central</p><p class="depth0">nervous system involvement under the appropriate system6309 Rheumatic fever:</p><p class="depth0">As active disease......................................         100</p><p class="depth0">Thereafter rate residuals such as heart damage under the appropriate</p><p class="depth0">system6310 Syphilis, and other treponemal infections:</p><p class="depth0">Rate the complications of nervous system, vascular system, eyes or</p><p class="depth0">ears. (See DC 7004, syphilitic heart disease, DC 8013,</p><p class="depth0">cerebrospinal syphilis, DC 8014, meningovascular syphilis, DC 8015,</p><p class="depth0">tabes dorsalis, and DC 9301, dementia associated with central</p><p class="depth0">nervous system syphilis)6311 Tuberculosis, miliary:</p><p class="depth0">As active disease......................................          100</p><p class="depth0">Inactive: See Sec.  Sec.   4.88c and 4.89.6313 Avitaminosis:</p><p class="depth0">Marked mental changes, moist dermatitis, inability to            100</p><p class="depth0">retain adequate nourishment, exhaustion, and cachexia.</p><p class="depth0">With all of the symptoms listed below, plus mental                60</p><p class="depth0">symptoms and impaired bodily vigor....................</p><p class="depth0">With stomatitis, diarrhea, and symmetrical dermatitis..           40</p><p class="depth0">With stomatitis, or achlorhydria, or diarrhea..........           20</p><p class="depth0">Confirmed diagnosis with nonspecific symptoms such as:            10</p><p class="depth0">decreased appetite, weight loss, abdominal discomfort,</p><p class="depth0">weakness, inability to concentrate and irritability...6314 Beriberi:</p><p class="depth0">As active disease:</p><p class="depth0">With congestive heart failure, anasarca, or Wernicke-            100</p><p class="depth0">Korsakoff syndrome....................................</p><p class="depth0">With cardiomegaly, or; with peripheral neuropathy with            60</p><p class="depth0">footdrop or atrophy of thigh or calf muscles..........</p><p class="depth0">With peripheral neuropathy with absent knee or ankle              30</p><p class="depth0">jerks and loss of sensation, or; with symptoms such as</p><p class="depth0">weakness, fatigue, anorexia, dizziness, heaviness and</p><p class="depth0">stiffness of legs, headache or sleep disturbance......</p><p class="depth0">Thereafter rate residuals under the appropriate body</p><p class="depth0">system.6315 Pellagra:</p><p class="depth0">Marked mental changes, moist dermatitis, inability to            100</p><p class="depth0">retain adequate nourishment, exhaustion, and cachexia.</p><p class="depth0">With all of the symptoms listed below, plus mental                60</p><p class="depth0">symptoms and impaired bodily vigor....................</p><p class="depth0">With stomatitis, diarrhea, and symmetrical dermatitis..           40</p><p class="depth0">With stomatitis, or achlorhydria, or diarrhea..........           20</p><p class="depth0">Confirmed diagnosis with nonspecific symptoms such as:            10</p><p class="depth0">decreased appetite, weight loss, abdominal discomfort,</p><p class="depth0">weakness, inability to concentrate and irritability...6316 Brucellosis:</p><p class="depth0">As active disease......................................         100</p><p class="depth0">Thereafter rate residuals such as liver or spleen damage or</p><p class="depth0">meningitis under the appropriate system6317 Typhus, scrub:</p><p class="depth0">As active disease, and for 3 months convalescence......         100</p><p class="depth0">Thereafter rate residuals such as spleen damage or skin conditions</p><p class="depth0">under the appropriate system6318 Melioidosis:</p><p class="depth0">As active disease......................................         100</p><p class="depth0">Thereafter rate residuals such as arthritis, lung lesions or</p><p class="depth0">meningitis under the appropriate system6319 Lyme Disease:</p><p class="depth0">As active disease......................................         100</p><p class="depth0">Thereafter rate residuals such as arthritis under the appropriate</p><p class="depth0">system6320 Parasitic diseases otherwise not specified:</p><p class="depth0">As active disease......................................         100</p><p class="depth0">Thereafter rate residuals such as spleen or liver damage under the</p><p class="depth0">appropriate system6350 Lupus erythematosus, systemic (disseminated):</p><p class="depth0">Not to be combined with ratings under DC 7809 Acute,             100</p><p class="depth0">with frequent exacerbations, producing severe</p><p class="depth0">impairment of health..................................</p><p class="depth0">Exacerbations lasting a week or more, 2 or 3 times per            60</p><p class="depth0">year..................................................</p><p class="depth0">Exacerbations once or twice a year or symptomatic                 10</p><p class="depth0">during the past 2 years...............................</p><p class="depth0">Note: Evaluate this condition either by combining the evaluations</p><p class="depth0">for residuals under the appropriate system, or by evaluating DC</p><p class="depth0">6350, whichever method results in a higher evaluation.</p><p class="depth0">6351 HIV-Related Illness:</p><p class="depth0">AIDS with recurrent opportunistic infections or with             100</p><p class="depth0">secondary diseases afflicting multiple body systems;</p><p class="depth0">HIV-related illness with debility and progressive</p><p class="depth0">weight loss, without remission, or few or brief</p><p class="depth0">remissions............................................</p><p class="depth0">Refractory constitutional symptoms, diarrhea, and                 60</p><p class="depth0">pathological weight loss, or; minimum rating following</p><p class="depth0">development of AIDS-related opportunistic infection or</p><p class="depth0">neoplasm..............................................</p><p class="depth0">Recurrent constitutional symptoms, intermittent                   30</p><p class="depth0">diarrhea, and on approved medication(s), or; minimum</p><p class="depth0">rating with T4 cell count less than 200, or Hairy Cell</p><p class="depth0">Leukoplakia, or Oral Candidiasis......................</p><p class="depth0">Following development of definite medical symptoms, T4            10</p><p class="depth0">cell of 200 or more and less than 500, and on approved</p><p class="depth0">medication(s), or; with evidence of depression or</p><p class="depth0">memory loss with employment limitations...............</p><p class="depth0">Asymptomatic, following initial diagnosis of HIV                   0</p><p class="depth0">infection, with or without lymphadenopathy or</p><p class="depth0">decreased T4 cell count...............................</p><p class="depth0">Note (1): The term ``approved medication(s)'' includes medications</p><p class="depth0">prescribed as part of a research protocol at an accredited medical</p><p class="depth0">institution.</p><p class="depth0">Note (2): Psychiatric or central nervous system manifestations,</p><p class="depth0">opportunistic infections, and neoplasms may be rated separately</p><p class="depth0">under appropriate codes if higher overall evaluation results, but</p><p class="depth0">not in combination with percentages otherwise assignable above.6354 Chronic Fatigue Syndrome (CFS):</p><p class="depth0">Debilitating fatigue, cognitive impairments (such as inability to</p><p class="depth0">concentrate, forgetfulness, confusion), or a combination of other</p><p class="depth0">signs and symptoms:</p><p class="depth0">Which are nearly constant and so severe as to restrict           100</p><p class="depth0">routine daily activities almost completely and which</p><p class="depth0">may occasionally preclude self-care...................</p><p class="depth0">Which are nearly constant and restrict routine daily              60</p><p class="depth0">activities to less than 50 percent of the pre-illness</p><p class="depth0">level, or; which wax and wane, resulting in periods of</p><p class="depth0">incapacitation of at least six weeks total duration</p><p class="depth0">per year..............................................</p><p class="depth0">Which are nearly constant and restrict routine daily              40</p><p class="depth0">activities to 50 to 75 percent of the pre-illness</p><p class="depth0">level, or; which wax and wane, resulting in periods of</p><p class="depth0">incapacitation of at least four but less than six</p><p class="depth0">weeks total duration per year.........................</p><p class="depth0">Which are nearly constant and restrict routine daily              20</p><p class="depth0">activities by less than 25 percent of the pre-illness</p><p class="depth0">level, or; which wax and wane, resulting in periods of</p><p class="depth0">incapacitation of at least two but less than four</p><p class="depth0">weeks total duration per year.........................</p><p class="depth0">Which wax and wane but result in periods of                      10</p><p class="depth0">incapacitation of at least one but less than two weeks</p><p class="depth0">total duration per year, or; symptoms controlled by</p><p class="depth0">continuous medication.................................</p><p class="depth0">Note: For the purpose of evaluating this disability, the condition</p><p class="depth0">will be considered incapacitating only while it requires bed rest</p><p class="depth0">and treatment by a physician.------------------------------------------------------------------------

[61 FR 39875, July 31, 1996]



Sec.  4.88c  Ratings for inactive nonpulmonary tuberculosis initially entitled after August 19, 1968.
------------------------------------------------------------------------</p><p class="depth0">Rating------------------------------------------------------------------------For 1 year after date of inactivity, following active                100</p><p class="depth0">tuberculosis...................................................Thereafter: Rate residuals under the specific body system or</p><p class="depth0">systems affected.Following the total rating for the 1 year period after date of</p><p class="depth0">inactivity, the schedular evaluation for residuals of</p><p class="depth0">nonpulmonary tuberculosis, i.e., ankylosis, surgical removal of</p><p class="depth0">a part, etc., will be assigned under the appropriate diagnostic</p><p class="depth0">code for the residual preceded by the diagnostic code for</p><p class="depth0">tuberculosis of the body part affected. For example,</p><p class="depth0">tuberculosis of the hip joint with residual ankylosis would be</p><p class="depth0">coded 5001-5250. Where there are existing residuals of</p><p class="depth0">pulmonary and nonpulmonary conditions, the evaluations for</p><p class="depth0">residual separate functional impairment may be combined.Where there are existing pulmonary and nonpulmonary conditions,</p><p class="depth0">the total rating for the 1 year, after attainment of</p><p class="depth0">inactivity, may not be applied to both conditions during the</p><p class="depth0">same period. However, the total rating during the 1-year period</p><p class="depth0">for the pulmonary or for the nonpulmonary condition will be</p><p class="depth0">utilized, combined with evaluation for residuals of the</p><p class="depth0">condition not covered by the 1-year total evaluation, so as to</p><p class="depth0">allow any additional benefit provided during such period.------------------------------------------------------------------------

[34 FR 5062, Mar. 11, 1969. Redesignated at 59 FR 60902, Nov. 29, 1994]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
